Aliskiren inhibits intracellular angiotensin ii levels without affecting (Pro)renin Receptor Signals in Human Podocytes

American Journal of Hypertension

Volumn 23, Issue 5, 2010, Pages 575-580

  Sakoda, Mariyo ^a,b   Ichihara, Atsuhiro ^a   Kurauchi Mito, Asako ^a   Narita, Tatsuya ^a   Kinouchi, Kenichiro ^a   Murohashi Bokuda, Kanako ^a   Saleem, Moin A ^c   Nishiyama, Akira ^d   Suzuki, Fumiaki ^e   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d KAGAWA UNIVERSITY   (Japan)

^e GIFU UNIVERSITY   (Japan)

Author keywords

Angiotensin; Blood pressure; Extracellular signal related protein kinase; Hypertension; Prorenin; SiRNA

Indexed keywords

ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRILAT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PRORENIN; RECOMBINANT PROTEIN; RENIN INHIBITOR; SMALL INTERFERING RNA;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY; PODOCYTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; WESTERN BLOTTING;

AMIDES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUMARATES; HUMANS; IMIDAZOLIDINES; PHOSPHORYLATION; PODOCYTES; RECEPTORS, CELL SURFACE; RENIN; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 77951104782     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.273     Document Type: Article

References (36)

1. Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005; 18(4 Pt 1):557-565.
2. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446.
3. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin\prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
4. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi P P, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin\prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99:1355-1366.
5. Batenburg WW, de Bruin RJ, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1151-1157.
6. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1\2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51:682-688.
7. Saris JJ, 't Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48:564-571.
8. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008; 19:743-748.
9. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52:130-136.
10. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113.
11. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72:45-52.
12. Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, Li PK, Szeto CC. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens 2009; 22:300-306.
13. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H. The (pro)renin receptor and the kidney. Semin Nephrol 2007; 27:524-528.
14. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13:630-638.
15. Durvasula RV, Shankland SJ. Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol Renal Physiol 2005; 289:F577-F584.
16. Petermann AT, Hiromura K, Blonski M, Pippin J, Monkawa T, Durvasula R, Couser WG, Shankland SJ. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 2002; 61:40-50.
17. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, Couser WG, Shankland SJ. Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005; 67:157-166.
18. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30-39.
19. Poorman RA, Palermo D P, Post LE, Murakami K, Kinner JH, Smith CW, Reardon I, Heinrikson RL. Isolation and characterization of native human renin derived from Chinese hamster ovary cells. Proteins 1986; 1:139-145.
20. Singh V P, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008; 294:H1675-H1684.
21. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y, Nabi AH, Nakagawa T, Suzuki F, Inagami T, Itoh H. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30:1139-1146.
22. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18:1789-1795.
23. Kaneshiro Y, Ichihara A, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Hayashi M, Inagami T. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70:641-646.
24. Singh V P, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008; 57:3297-3306.
25. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89:1138-1146.
26. Fisher ND, Jan Danser AH, Nussberger J, Dole W P, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
27. Tagawa K, Mizobe M, Noda K. A saturable tissue-angiotensin I converting enzyme (ACE) binding model for the pharmacokinetic analysis of imidapril, a new ACE inhibitor, and its active metabolite in human. Biol Pharm Bull 1995; 18:64-69.
28. Gleiter CH, Mörike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002; 41:7-17.
29. Belz GG, Butzer R, Kober S, Mutschler E. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J Cardiovasc Pharmacol 2002; 39: 561-568.
30. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62:690-698.
31. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996; 14:799-805. (Pubitemid 26187416)
32. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5:408-417.
33. Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, Sugawara A, Nakao K. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16:2690-2701.
34. Huang Y, Border WA, Noble NA. Functional renin receptors in renal mesangial cells. Curr Hypertens Rep 2007; 9:133-139.
35. Liebau MC, Lang D, Böhm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstädt H, Fischer KG. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 290:F710-F719.
36. Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med 2008; 86:623-627.